Edition:
United Kingdom

Pharming Group NV (PHAR.AS)

PHAR.AS on Amsterdam Stock Exchange

1.17EUR
15 Dec 2017
Change (% chg)

€-0.03 (-2.75%)
Prev Close
€1.20
Open
€1.20
Day's High
€1.20
Day's Low
€1.16
Volume
12,736,036
Avg. Vol
30,844,325
52-wk High
€1.38
52-wk Low
€0.22

Latest Key Developments (Source: Significant Developments)

Pharming Group Announces Significant Conversion Of Its Ordinary Convertible Bonds
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - PHARMING GROUP NV ::PHARMING ANNOUNCES SIGNIFICANT CONVERSION OF ITS ORDINARY CONVERTIBLE BONDS.‍BONDHOLDERS CONVERT 26% (EUR 3.0 MILLION) OF THEIR BONDS INTO PHARMING SHARES​.REDUCES OUTSTANDING AMOUNT OF BONDS TO EUR 8.5 MILLION.ISSUES 10,563,380 SHARES FROM WITHIN AMOUNT ALLOCATED TO CONVERSION OF ORDINARY CONVERTIBLE BONDS.NUMBER OF SHARES ISSUED REPRESENTS 2.0% OF OUTSTANDING SHARES IMMEDIATELY BEFORE ISSUE.  Full Article

Pharming Submits License Application to FDA for Ruconest
Monday, 27 Nov 2017 

Nov 27 (Reuters) - PHARMING GROUP NV ::PHARMING SUBMITS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION TO FDA FOR RUCONEST® FOR PROPHYLAXIS OF HEREDITARY ANGIOEDEMA ATTACKS.‍TWO STUDIES ENROLLED A TOTAL OF 56 PATIENTS AND SHOWED CONSISTENT EFFICACY AND SAFETY RESULTS​.  Full Article

Pharming Group Q3 net result swings to profit of 7.5 million euros from Q2
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - PHARMING GROUP NV ::‍Q3 NET RESULT IMPROVED TO EUR 7.5 MILLION LOSS COMPARED WITH A LOSS OF EUR 24.5 MILLION IN Q2​.‍Q3 OPERATING PROFIT UP TO EUR 8.5 MILLION COMPARED WITH A LOSS OF EUR 3.2 MILLION IN Q3 2016​.‍REVENUES FOR NINE MONTHS TO 30 SEPTEMBER INCREASED TO EUR 56.7 MILLION (2016 EUR 8.7 MILLION)​.‍EXPECTS FY 2017 REVENUES FROM PRODUCT SALES TO EXCEED ANALYSTS' FORECASTS ​.‍POSITIVE CASHFLOWS DURING Q3 INCREASED CASH POSITION TO EUR 38.6 MILLION FROM EUR 25.2 MILLION AT JUNE 30 2017​.9 MONTHS GROSS PROFIT EUR 48.8‍​ MILLION VERSUS EUR 5.5 MILLION YEAR AGO.‍EXPECTS Q4 RESULTS TO EXCEED Q3 SIGNIFICANTLY​.‍EXPECTS ACHIEVEMENT OF CONTINUED OPERATING PROFIT AND POSITIVE CASHFLOWS FOR REMAINING QUARTER​.  Full Article

Pharming Group announces positive data from paediatric clinical trial of Ruconest
Monday, 2 Oct 2017 

Oct 2 (Reuters) - PHARMING GROUP NV ::PHARMING ANNOUNCES POSITIVE DATA FROM PAEDIATRIC CLINICAL TRIAL WITH RUCONEST®.‍MEDIAN TIME TO ONSET OF RELIEF WAS 60 MINUTES​.‍MEDIAN TIME TO MINIMAL SYMPTOMS WAS 122 MINUTES​.‍ONLY 3/73 (4%) ATTACKS WERE TREATED WITH A SECOND DOSE OF RUCONEST®.​.‍RUCONEST® WAS GENERALLY SAFE AND WELL-TOLERATED IN STUDY​.‍NO PATIENTS WITHDREW FROM STUDY DUE TO ADVERSE EVENTS.​.‍STUDY REPORTED CLINICALLY MEANINGFUL RELIEF OF SYMPTOMS​.  Full Article

Pharming announces conclusion of FDA end of phase 2 interactions on Ruconest
Monday, 11 Sep 2017 

Sept 11 (Reuters) - PHARMING GROUP NV :PHARMING ANNOUNCES CONCLUSION OF FDA END OF PHASE 2 INTERACTIONS ON RUCONEST FOR PROPHYLAXIS OF HAE.TO SUBMIT IN Q4 TO FDA FOR REVIEW BLA EFFICACY SUPPLEMENT (SBLA) TO INCLUDE ROUTINE PROPHYLAXIS AGAINST ANGIOEDEMA ATTACKS IN ADOLESCENT AND ADULT PATIENTS WITH HAE​.  Full Article

Pharming Group 8-month product sales rise to 6.2 million euros
Monday, 3 Oct 2016 

Pharming Group Nv : 8-month product sales 6.2 million euros ($6.97 million)versus 5.6 million euros year ago . 8-month operating loss 8.3 million euros versus loss of 8.1 million euros year ago . Expect that both sales and gross profits will continue to improve during remainder of year and that investments in research and development will continue to increase gradually. .Would expect to become profitable at operating level during 2017.  Full Article

Valeant Pharmaceuticals Q2 GAAP loss per share $0.88
Tuesday, 9 Aug 2016 

Valeant Pharmaceuticals International Inc : Valeant Pharmaceuticals reports second quarter 2016 financial results . Sees FY 2016 revenue $9.9 billion to $10.1 billion . Q2 earnings per share view $1.48 -- Thomson Reuters I/B/E/S . Q2 GAAP loss per share $0.88 . "we have taken steps to streamline our portfolio in Q2" . Entered into a definitive agreement to divest all north american commercialization rights to Ruconest to Pharming Group N.V. . Sold, or agreed to sell, brodalumab EU rights, synergetics USA OEM business, and Ruconest® for a total combined upfront payment of $181 million . Pharming will also pay valeant certain sales-based milestone payments of up to $65 million . Brodalumab EU rights,synergetics USA OEM business,Ruconest deal includes additional consideration up to $329 million for approval,sales milestones . Total revenues decreased 11% to $2.42 billion in Q2 of 2016 . Q2 earnings per share view $1.44, revenue view $2.45 billion -- Thomson Reuters I/B/E/S . Valeant Pharmaceuticals international inc qtrly adjusted earnings per share $1.40 . Company is reconfirming its full year 2016 guidance . Announcing new strategic direction for Valeant, which will involve reorganizing our company and reporting segments . Pharming will pay valeant aggregate consideration of up to $125 million, including an upfront fee of $60 million payable upon closing.  Full Article

Pharming Group H1 operating loss at 6.2 million euros
Thursday, 28 Jul 2016 

Pharming Group Nv : H1 revenues 5.3 million euros ($5.86 million) versus 5.2 million euros year ago . H1 operating loss 6.2 million euros versus loss of 6.1 million euros year ago . H1 total cash and cash equivalent position (including restricted cash) decreased by 10.1 million euros from 31.8 million euros at year-end 2015 to 21.7 million euros at the end of June 2016 .Accounting net loss increased from 3.5 million euros in the first half of 2015 to 6.7 million euros in the first half of 2016.  Full Article

Pharming Group amends Ruconest distribution agreement with Sobi
Thursday, 14 Jul 2016 

Pharming Group NV : Pharming amends ruconest distribution agreement with Sobi . Pharming to directly commercialise Ruconest in 21 additional Western European, North African and Middle-Eastern markets .Pharming will expand current small European team of experienced hae marketing and medical affairs specialists.  Full Article

Pharming Group Q1 net loss widens to 3.4 million euros
Wednesday, 18 May 2016 

Pharming Group Nv : Net loss increased from 1.3 million euros ($1.47 million) in Q1 2015 to 3.4 million euros in Q1 2016 . Gross profits from sales continue to increase though; from 0.8 million euros in Q1 2015 and 1.2 million euros in Q4 2015 to 1.6 million euros in Q1 2016 .Q1 revenues 2.2 million euros versus 1.8 million euros year ago.  Full Article